Exabis Library
Welcome to the e-CCO Library!
P411: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P411: Early ultrasound assessment predicts therapy response: an easy tool for clinical decision making
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P411: Four-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P411: Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P411: Using wearable devices to assess pain in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P412 Maintenance therapy of vedolizumab (VDZ) after induction of remission by tacrolimus (TAC) in patients with refractory ulcerative colitis (UC)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P412: Drug persistence and endoscopic, histologic and biochemical remission rates among patients following ileal pouch-anal anastomosis treated with biologic therapy: Results from a prospective patient cohort.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P412: Effectiveness of ustekinumab in fistulising perianal Crohn´s disease refractory or intolerant to anti-TNF
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P412: Efficacy and safety of additional autologous platelet-rich stroma in transanal mucosal advancement flap repair of complex cryptoglandular anal fistulas
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P412: Evolution of patients with ulcerative colitis who withdraw the maintenance treatment with mesalazine
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P412: The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P412: Time trend in clinicopathological features and prognosis of Ulcerative Colitis associated neoplasia: A nationwide cohort in Japan
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P412: White cell count (WCC) and mean corpuscular volume (MCV) as surrogate markers for thiopurine monitoring in inflammatory bowel disease (IBD) treatment: A single-centre experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P413 General impressions about nutrition in patients with inflammatory bowel disease using a nutritional survey
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P413: A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P413: Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b2 vaccines in the immunosuppressed (RESCUE)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P413: Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn`s disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P413: Endoscopic balloon dilatation of Crohn’s strictures is safe and effective in selected cases
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P413: Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P413: Relative frequency of relapses in patients with ulcerative colitis and Crohn's disease treated with mesenchymal stromal cells: Five-years of follow-up
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM